Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of “Hold” by Analysts

Shares of Kodiak Sciences Inc. (NASDAQ:KODGet Rating) have received a consensus rating of “Hold” from the nine brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $48.63.

Several analysts recently weighed in on KOD shares. Barclays cut their price target on Kodiak Sciences from $81.00 to $50.00 and set an “underweight” rating on the stock in a research note on Monday, February 7th. JPMorgan Chase & Co. downgraded Kodiak Sciences from an “overweight” rating to a “neutral” rating and cut their target price for the company from $90.00 to $21.00 in a research note on Thursday, February 24th. Citigroup cut their target price on Kodiak Sciences from $70.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, February 24th. Truist Financial cut their target price on Kodiak Sciences from $147.00 to $35.00 in a research note on Thursday, February 24th. Finally, The Goldman Sachs Group began coverage on Kodiak Sciences in a research note on Friday, February 11th. They set a “buy” rating and a $70.00 target price on the stock.

Kodiak Sciences stock opened at $6.92 on Monday. The company has a market capitalization of $359.52 million, a P/E ratio of -1.15 and a beta of 1.98. The stock’s 50 day moving average is $6.76 and its 200 day moving average is $43.24. Kodiak Sciences has a twelve month low of $4.90 and a twelve month high of $26.39.

Kodiak Sciences (NASDAQ:KODGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($1.83) earnings per share for the quarter, missing the consensus estimate of ($1.51) by ($0.32). During the same period in the prior year, the firm posted ($0.98) earnings per share. Research analysts predict that Kodiak Sciences will post -6.64 earnings per share for the current fiscal year.

In other news, Director Bros. Advisors Lp Baker purchased 223,766 shares of the stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average cost of $5.97 per share, with a total value of $1,335,883.02. Following the acquisition, the director now directly owns 15,142,074 shares of the company’s stock, valued at $90,398,181.78. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 39.70% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the business. Lindbrook Capital LLC raised its holdings in Kodiak Sciences by 2,160.0% during the fourth quarter. Lindbrook Capital LLC now owns 565 shares of the company’s stock valued at $48,000 after acquiring an additional 540 shares during the period. US Bancorp DE raised its holdings in Kodiak Sciences by 53.5% during the third quarter. US Bancorp DE now owns 508 shares of the company’s stock valued at $49,000 after acquiring an additional 177 shares during the period. Marshall Wace North America L.P. bought a new stake in Kodiak Sciences during the first quarter valued at about $73,000. Exane Derivatives grew its position in shares of Kodiak Sciences by 8,472.7% during the fourth quarter. Exane Derivatives now owns 943 shares of the company’s stock valued at $80,000 after purchasing an additional 932 shares in the last quarter. Finally, Tiedemann Advisors LLC purchased a new position in shares of Kodiak Sciences during the first quarter valued at about $92,000. 69.80% of the stock is currently owned by institutional investors and hedge funds.

About Kodiak Sciences (Get Rating)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Recommended Stories

Analyst Recommendations for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.